摘要
目的探究氯呲格雷对冠心病介入治疗后发生心血管不良事件的预防效果。方法64例进行介入治疗的冠心病患者,采用随机盲选的方式分为观察组和对照组,每组32例。对照组行低分子肝素治疗,观察组行氯呲格雷治疗。比较两组用药后6、12、24 h的血栓素B2水平及心血管不良事件发生情况。结果观察组患者用药后6、12、24 h的血栓素B2水平分别为(82.21±14.86)、(65.10±12.51)、(46.69±9.10)ng/L,均低于对照组的(93.17±16.48)、(75.40±15.03)、(66.92±11.03)ng/L,差异均有统计学意义(P<0.05)。观察组心血管不良事件发生率为9.38%,低于对照组的31.25%,差异有统计学意义(P<0.05)。结论氯呲格雷对冠心病介入治疗后发生心血管不良事件的临床预防效果显著,亦可改善机体血栓素B2水平,值得推广。
Objective To investigate the prevention effect of clopidogrel on cardiovascular adverse events after percutaneous coronary intervention.Methods A total of 64 patients with coronary heart disease after interventional therapy were randomly divided into control group and observation group,with 32 cases in each group.The control group was treated with low molecular weight heparin,and the observation group was treated with clopidogrel.The levels of thromboxane B2 at 6,12 and 24 h after administration,and the occurrence of cardiovascular adverse events were compared between the two groups.Results The levels of thromboxane B2 at 6,12 and 24 h after administration of the observation group were(82.21±14.86),(65.10±12.51)and(46.69±9.10)ng/L,which were lower than(93.17±16.48),(75.40±15.03)and(66.92±11.03)ng/L of the control group,and the difference was statistically significant(P<0.05).The incidence of cardiovascular adverse events of the observation group was 9.38%,which was lower than 31.25%of the control group,and the difference was statistically significant(P<0.05).Conclusion Clopidogrel has remarkable preventive effect for the occurrence of cardiovascular adverse events,and it can improve the levels of thromboxane B2.It is worthy of promotion.
作者
陈颖
CHEN Ying(Fuxin Second People’s Hospital(Fuxin Obstetrics and Gynecology Hospital),Fuxin 123000,China)
出处
《中国现代药物应用》
2020年第24期109-111,共3页
Chinese Journal of Modern Drug Application
关键词
氯呲格雷
冠心病
介入治疗
心血管不良事件
临床效果
Clopidogrel
Coronary heart disease
Interventional therapy
Cardiovascular adverse events
Clinical effect
